前列腺癌阴性多参数磁共振后的临床结局与随访策略
该研究回顾性分析了单中心7年间1545例前列腺阴性多参数磁共振(nMRI)患者,其中1255例纳入分析并分为初诊组和既往活检阴性组。随访显示nMRI对排除临床显著前列腺癌(csPCa)高度可靠,但高龄、高PSA及高PSA密度仍预测csPCa诊断,作者建议nMRI后仍应行系统活检。
要点
- nMRI后2年任何级别PCa和csPCa无诊断生存率初诊组分别为94%和95%,既往活检阴性组均为96%。
- 随访48个月,初诊组任何级别PCa无诊断生存率降至84%,既往活检阴性组保持96%。
- 年龄增长独立预测较低csPCa诊断概率,PSA和PSA密度升高独立预测较高csPCa诊断概率。
核心结论
- mpMRI对排除csPCa高度可靠,但nMRI后仍应推荐系统活检,尤其对年轻、PSA高或升高的患者。
研究设计与样本
- 回顾性分析2010年1月至2015年5月单中心所有mpMRI,筛选nMRI患者并分为初诊组(A组)和既往活检阴性组(B组)。
- 共1545例nMRI患者,1255例符合纳入标准,A组659例,B组596例;未诊断PCa者随访至少2年且至少两次连续nMRI。
主要发现
- 随访2年,A组任何级别PCa和csPCa无诊断生存率分别为94%和95%,B组均为96%。
- 随访48个月,A组任何级别PCa无诊断生存率为84%,B组为96%(log rank p<0.001);csPCa无诊断生存率48个月后无变化。
- 多因素Cox回归显示年龄增长(p=0.005)独立预测较低csPCa诊断概率,PSA和PSA密度升高(<0.001)独立预测较高csPCa诊断概率。
- csPCa患病率为31.6%,阳性预测值为45.5%。
临床怎么用
- mpMRI阴性可用于排除csPCa,但不应据此省略系统活检。
- 对年轻、PSA高或升高的患者,即使mpMRI阴性仍应推荐系统活检。
局限性
- 随访时间有限。
- 无法计算研究人群中真实csPCa患病率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiparametric magnetic resonance imaging (mpMRI) of the prostate has excellent sensitivity in detecting clinically significant prostate cancer (csPCa). Nevertheless, the clinical utility of negative mpMRI (nMRI) is less clear. OBJECTIVE: To assess outcomes of men with nMRI and clinical follow-up after 7 yr of activity at a reference center. DESIGN, SETTING, AND PARTICIPANTS: All mpMRI performed from January 2010 to May 2015 were reviewed. We selected all patients with nMRI and divided them in group A (naïve patients) and group B (previous negative biopsy). All patients without a diagnosis of PCa had a minimum follow-up of 2 yr and at least two consecutive nMRI. Patients with positive mpMRI were also identified to assess their biopsy outcomes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A Kaplan-Meier analysis was performed to assess both any-grade PCa and csPCa diagnosis-free survival probabilities. Univariable and multivariable Cox regression models were fitted to identify predictors of csPCa diagnosis. RESULTS AND LIMITATIONS: We identified 1545 men with nMRI, and 1255 of them satisfied the inclusion criteria; 659 belonged to group A and 596 to group B. Any-grade PCa and csPCa diagnosis-free survival probabilities after 2 yr of follow-up were 94% and 95%, respectively, in group A; in group B, they were 96%. After 48 mo of follow-up, any-grade PCa diagnosis-free survival probability was 84% in group A and 96% in group B (log rank p<0.001). Diagnosis-free survival probability for csPCa was unchanged after 48 mo of follow-up. On multivariable Cox regression analysis, increasing age (p=0.005) was an independent predictor of lower csPCa diagnosis probability, while increasing prostate-specific antigen (PSA) and PSA density (<0.001) independently predicted higher csPCa diagnosis probability. The prevalence of and positive predictive value for csPCa were 31.6% and 45.5%, respectively. Limitations include limited follow-up and the inability to calculate true csPCa prevalence in the study population. CONCLUSIONS: mpMRI is highly reliable to exclude csPCa. Nevertheless, systematic biopsy should be recommended even after nMRI, especially in younger patients with high or raising PSA levels. PATIENT SUMMARY: It is a matter of debate whether patients with negative multiparametric magnetic resonance imaging (mpMRI) of the prostate could obviate the need to perform a systematic biopsy. In this report, we looked at the outcomes of patients with negative mpMRI and midterm clinical follow-up at a reference center. We found mpMRI to be highly reliable to exclude significant prostate cancer; nonetheless, systematic biopsy must still be recommended after negative mpMRI in patients with high clinical suspicion of prostate cancer.
引用
- Panebianco V, Barchetti G, Simone G, et al. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next? Eur Urol. 2018. PMID: 29566957. doi:10.1016/j.eururo.2018.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。